Advancement of HER-2 positive breast cancer treatment in 2023

doi:10.3877/cma.j.issn.1674-0807.2024.02.002

Abstract

Abstract:

HER-2 positive breast cancer is an aggressive and highly malignant subtype accounting for 20%-25% of all breast cancer, with a poor prognosis. In recent years, with the in-depth understanding of biological characteristics of HER-2 positive breast cancer and its related signaling pathways, new targeted drugs have been developed and new strategies of combination therapies have brought encouraging outcomes. In this article, we reviews the research progress of HER-2 positive breast cancer in early and late stages in 2023, as well as therapeutic breakthroughs in patients with brain metastases, and then discusses key issues and research directions that may change clinical practice in the future.

Key words: Breast neoplasms, Receptor, ErbB-2, Brain metastases, Drug therapy, combination, Antibody-drug conjugate

Peng Yuan. Advancement of HER-2 positive breast cancer treatment in 2023[J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(02): 66-70.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2024.02.002

https://zhrxbzz.cma-cmc.com.cn/EN/Y2024/V18/I02/66

References 34

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71(3)：209-249.
[2]	Oh DY, Bang YJ. HER2-targeted therapies-a role beyond breast cancer[J]. Nat Rev Clin Oncol，2020，17(1)：33-48.
[3]	Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now[J]. NPJ Breast Cancer，2021，7(1)：56.
[4]	Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol，2014，32(33)：3744-3752.
[5]	von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med，2019，380(7)：617-628.
[6]	Sibylle L, Max M, Michael U, et al. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis [EB/OL]. [2024-03-01]. URL
[7]	Hurvitz SA, Bachelot T, Bianchini G, et al. ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer[J]. Future Oncol，2022，18(32)：3563-3572.
[8]	O’Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1＋tucatinib/placebo in patients with residual HER2-positive invasive breast cancer[J]. Future Oncol，2021，17(34)：4665-4676.
[9]	Geyer CE Jr, Untch M, Prat A, et al. Abstract OT-03-01: trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05) [J]. Cancer Res，2021，81(Suppl 4)：OT-03-01
[10]	Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol，2006，24(18)：2786-2792.
[11]	Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol，2020，21(4)：519-530.
[12]	Ma F, Yan M, Li W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial[J]. BMJ，2023，383：e076065.
[13]	Qingyuan Z, Jingxuan W, Quchang O, et al. Two and a half years follow-up data of HER2-targeted bispecific antibody KN026 combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer[EB/OL]. [2024-03-01]. URL
[14]	Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial[J]. Lancet，2023，401(10371)：105-117.
[15]	National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) breast cancer version 2.2024[EB/OL]. [2024-03-01]. URL
[16]	中国抗癌协会乳腺癌专业委员会，中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志，2023, 33(12): 1092-1187.
[17]	Sara H, Sherene L, Joyce OS, et al. HER2CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated Her2-positive metastatic breast cancer[EB/OL]. [2024-03-01]. URL
[18]	Aftimos PG, Turner N, O’Shaughnessy J, et al. 386MO Trastuzumab duocarmazine versus physician’s choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial[EB/OL]. [2024-03-01]. URL
[19]	Adrienne W, Ruichao S, Meredith R, et al. AVIATOR/TBCRC045: a randomized phase II study of vinorelbine (N) ＋ trastuzumab (H) alone or combined with avelumab (A) ＋/－ utomilumab (U) in patients (pts) with HER2＋ metastatic breast cancer (MBC) (NCT03414658)[EB/OL]. [2024-03-01]. URL
[20]	Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial[J]. Lancet Oncol，2020，21(10)：1283-1295.
[21]	Herui Y, Min YZ, Zhongsheng T, et al. Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: a global phase 1, multi-center, first-in-human study [J]. Cancer Res，2023，83(8 Suppl)：Abstract nr CT175.
[22]	Qiao L, Ying C, Zhongsheng T, et al. FS-1502 in HER2-positive advanced breast cancer: results from an open-label, phase 1 study[J]. J Clin Oncol，2023, 41(16 Suppl)：3044.
[23]	Fei M, Nong X, Huoling T, et al. A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors[J]. Munster J Clin Oncol, 2023, 41(16 Suppl)：3029.
[24]	Lin NU, Amiri-Kordestani L, Palmieri D, et al. CNS metastases in breast cancer: old challenge, new frontiers[J]. Clin Cancer Res，2013，19(23)：6404-6418.
[25]	Niu L, Lv H, Zhang M, et al. Clinical diagnosis and treatment of breast cancer with brain metastases and establishment of a prognostic model: a 10-year, single-center, real-world study of 559 cases[J]. Ann Transl Med，2021，9(16)：1331.
[26]	Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update[J]. J Clin Oncol，2018，36(27)：2804-2807.
[27]	Mair MJ, Bartsch R, Le Rhun E, et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours[J]. Nat Rev Clin Oncol，2023，20(6)：372-389.
[28]	Hurvitz SA, Modi S, Li W, et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2＋) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03[EB/OL]. [2024-03-01]. URL
[29]	AstraZeneca.Trastuzumab deruxtecan (T-DXd) alone or in sequence with THP, versus standard treatment (ddAC-THP), in HER2-positive early breast cancer [EB/OL]. [2024-03-01]. URL
[30]	Javier C, José MP, Manuel RB, et al. 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[＋]) early breast cancer (EBC) [J]. J Clin Oncol，2023，41(17 Suppl)：LBA506.
[31]	Pier FC, Giancarlo B, Federico P, et al. Nine-weeks versus one-year trastuzumab for early-stage HER2＋ breast cancer: 10-year update of the Short-HER phase III randomized trial [J]. J Clin Oncol，2023，41(17 Suppl)：LBA637.
[32]	AstraZeneca. Trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive metastatic breast cancer (DESTINY-Breast09) [EB/OL]. [2024-03-01]. URL
[33]	Shanghai JMT-Bio Inc. Efficacy and safety of KN026 in combination with HB1801 in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer [EB/OL]. [2024-03-01]. URL
[34]	Lin NU, Ciruelos E, Jerusalem G, et al. Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2＋ BC): DESTINY-Breast12[EB/OL]. [2024-03-01]. URL

Please choose a citation manager

Content to export